Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28020656 | 0.77 | — | — | |
| SCHEMBL6009568 | 0.76 | HSP90AA1 (0.41) | CYP3A4MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL12522489 | 0.76 | HSP90AA1 (0.41) | CYP3A4MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL280131 | 0.76 | HSP90AA1 (0.41) | CYP3A4MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL267258 | 0.69 | CYP3A4 (0.36) | CYP3A4MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL10799569 | 0.66 | FDPS (0.33) | CYP3A4MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL10799566 | 0.66 | FDPS (0.33) | CYP3A4MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL267483 | 0.64 | ALDH1A1 (0.31) | CYP3A4ALDH1A1CYP2C9TSHRCYP2C19 | |
| SCHEMBL15647555 | 0.63 | ALDH1A1 (0.40) | CYP3A4MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL17379691 | 0.63 | ALDH1A1 (0.30) | CYP3A4ALDH1A1CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238634-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8133915-B2 | Interleukin-1 and tumor necrosis factor-α modulators; syntheses of such modulators and methods of using such modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110160309-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238634-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | IL1A, IL1B, TNF | CYP3A4 2799/4885MAPT 4689/4885MEN1 54/4885 |
| US-20110160309-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | IL1A, IL1B, TNF | CYP3A4 2799/4885MAPT 4689/4885MEN1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.